Daily Medication Pearl: Tavneos (avacopan) for Severe Active Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis

Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a.

Indication: Tavneos is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.

Insight:

  • Dosing:The recommended dosage is 30 mg (three 10 mg capsules) twice daily, with food.
  • Dosage form: 10 mg capsules
  • Adverse events: The most common adverse reactions (≥5%) include nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia.
  • Mechanism of action:Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Avacopan blocks C5a-mediated neutrophil activation and migration.
  • Manufacturer: ChemoCentryx

References